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Community member perspectives from
transgender women and men who have sex with
men on pre-exposure prophylaxis as an HIV
prevention strategy: implications for
implementation
Gabriel R Galindo1,3*, Ja’Nina J Walker1,2, Patrick Hazelton1, Tim Lane1, Wayne T Steward1, Stephen F Morin1
and Emily A Arnold1
Abstract
Background: An international randomized clinical trial (RCT) on pre-exposure prophylaxis (PrEP) as an human
immunodeficiency virus (HIV)-prevention intervention found that taken on a daily basis, PrEP was safe and effective
among men who have sex with men (MSM) and male-to-female transgender women. Within the context of the HIV
epidemic in the United States (US), MSM and transgender women are the most appropriate groups to target for
PrEP implementation at the population level; however, their perspectives on evidenced-based biomedical research
and the results of this large trial remain virtually unknown. In this study, we examined the acceptability of individual
daily use of PrEP and assessed potential barriers to community uptake.
Methods: We conducted semi-structured interviews with an ethnoracially diverse sample of thirty HIV-negative and
unknown status MSM (n = 24) and transgender women (n = 6) in three California metropolitan areas. Given the
burden of disease among ethnoracial minorities in the US, we purposefully oversampled for these groups. Thematic
coding and analysis of data was conducted utilizing an approach rooted in grounded theory.
Results: While participants expressed general interest in PrEP availability, results demonstrate: a lack of community
awareness and confusion about PrEP; reservations about PrEP utilization, even when informed of efficacious RCT
results; and concerns regarding equity and the manner in which a PrEP intervention could be packaged and
marketed in their communities.
Conclusions: In order to effectively reduce HIV health disparities at the population level, PrEP implementation must
take into account the uptake concerns of those groups who would actually access and use this biomedical
intervention as a prevention strategy. Recommendations addressing these concerns are provided.
Keywords: Men who have sex with men (MSM), Male-to-female (MTF) transgender women, HIV/AIDS, Pre-exposure
prophylaxis (PrEP), Qualitative research, Health disparities
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Background
‘A pill a day reduces risk for HIV infection’ [1]. Pub-
lished in November 2010, this San Francisco Depart-
ment of Public Health press release headline trumpeted
a new era of human immunodeficiency virus (HIV) pre-
vention as the results of a recent international rando-
mized clinical trial (RCT) demonstrated that daily use of
a combination antiretroviral pill (TruvadaW) reduced
HIV infections by 44%, overall, among HIV-negative sta-
tus men who have sex with men (MSM) and male-to-
female transgender women [2]. The trial, known as the
iPrEx Study, assessed the efficacy of pre-exposure
prophylaxis (PrEP) for HIV prevention when given as
part of a comprehensive package of prevention services.
The policy implications of the iPrEx Study data, promot-
ing the use of PrEP to prevent HIV transmission at the
population level, are being widely discussed [3-5]. How-
ever, before addressing the important issues of cost and
delivery systems, even more fundamental implementa-
tion questions remain about community acceptability.
Would those at highest risk be willing to take a pill a
day? How does this approach fit with the way people
think about their risk of HIV infection? In this study we
explore, through semi-structured interviews with MSM
and transgender women in three California counties,
how some of these individuals understand the issues
posed by PrEP and put forth relevant implementation
recommendations.
Globally, there are 2.7 million new HIV infections an-
nually; with the rate of new transmissions outpacing the
rate at which HIV-positive diagnosed individuals enter
treatment [6]. In this global epidemic MSM and trans-
gender women who have sex with men bear a major
portion of the burden [7,8]. In the United States (US),
there are currently over one million persons living with
HIV/AIDS, with MSM populations constituting over half
(53%) of new infections annually [9]. In California, MSM
represent 61%, 72%, and 73% of living HIV/AIDS cases
in Alameda [10], Los Angeles [11] and San Francisco
[12] counties, respectively. Among transgender women,
a recent review estimated HIV prevalence in the US be-
tween 11% and 28% [13]. Overall, the incidence of HIV
in the US has remained stable in recent years; however,
MSM and transgender women are the only groups for
which HIV infection and AIDS diagnosis rates continue
to rise [6].
The National HIV/AIDS Strategy for the US reports
that ethnoracial health disparities in HIV infections exist
as Black and Latino MSM are disproportionately
affected by the epidemic, and increased attention to
these populations is needed [9,14]. A recent review of
behavioral HIV interventions among MSM noted that
while continued research is needed to identify which
specific strategies are most effective in reducing
transmission, and which intervention components are
most effective in influencing those behaviors, US feder-
ally funded programs have had an effect in reducing
HIV transmissions [15]. In fiscal year 2010, US Depart-
ment of Health and Human Services domestic spending
on direct prevention, care, and treatment of HIV/AIDS
totaled nearly $9.7 billion, with 70% of those funds going
toward direct client services through the Centers for
Medicare and Medicaid [16]. Even in an era of fiscal
conservatism, the US government has committed itself
to supporting HIV prevention programming and ser-
vices, particularly for those communities most impacted
[17].
The potential of PrEP as an HIV prevention tool
For sexually active individuals, the use of male condoms
has remained the most cost-effective and readily access-
ible prevention tool for nearly three decades. While con-
dom promotion interventions alone have had success in
reducing HIV infections, new biomedical strategies for
preventing transmission, including male circumcision,
vaccines, topical microbicides, and the use of oral anti-
retroviral (ARV) medication as prophylaxis, have in-
creasingly been under study [18]. Recent work has
acknowledged the role of comprehensive services in de-
creasing HIV disparities among MSM [19,20]. According
to the Centers for Disease Control and Prevention
(CDC), PrEP is an HIV prevention method that requires
HIV-negative individuals to take a daily pill to reduce
their risk of becoming infected [21]. To date, three stud-
ies of PrEP reported successful reductions in HIV infec-
tions among heterosexual men and women [22]. The
iPrEx Study, which included MSM and transgender
women, remains the sole PrEP trial shown to be effective
in populations who would benefit most from implemen-
tation in the context of the US HIV epidemic. A total of
2,499 individuals, 99% MSM and 1% transgender
women, from six nations participated in the eleven-site
iPrEx Study [2,23]. The study design consisted of all par-
ticipants receiving a comprehensive package of ongoing
prevention services and health monitoring, including: in-
tensive safer sex counseling, frequent dosing of condom
promotion and distribution, screening of sexually trans-
mitted infections (STIs) every 24 weeks or when war-
ranted, monthly HIV testing, and select laboratory
examinations.
Results from the study demonstrated an overall 44%
(95% CI: 15, 63) reduction in HIV infection. Among
those whose self-reported adherence was 90% or more,
risk of HIV infection was reduced by 73% (95% CI: 41,
88). Initial data gauging attitudes of PrEP acceptability
among MSM populations were conducted prior to the
release of iPrEx Study results, and did not include trans-
gender women. These findings have indicated a general
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lack of knowledge surrounding PrEP, but a willingness
for utilization once aware of the potential for HIV pre-
vention [24,25]. One study, which presented 25 HIV ser-
odiscordnant MSM couples with a hypothetical 90%
PrEP efficacy rate, gave unique insights into factors that
could influence uptake within a partner relationship, but
was limited in extending these findings to those not in a
partner relationship [26].
While literature on acceptability among ethnoracial
minorities and transgender women community members
is scarce, two studies since the release of the iPrEx
results have shown that interest and use of PrEP among
MSM varied across populations. One study, which
sampled MSM engaged in online networking, noted that
awareness of PrEP was limited one month after the
iPrEx data were released and that utilization was ex-
tremely rare, despite the fact that MSM who reported
high-risk behaviors were interested in using PrEP [27].
The other study, based in Australia, reported that high-
risk MSM (i.e., those reporting unprotected anal inter-
course with another man) indicated a willingness to use
PrEP; however, factors that would either increase or de-
crease their willingness were not ascertained in that
quantitative investigation [28]. The goal of this study is
to explore the factors surrounding PrEP acceptability
among community members from populations dispro-
portionately affected by the US HIV epidemic.
Methods
Previous international qualitative work with MSM popu-
lations has been useful in providing nuanced under-
standings of sexuality, risk behaviors, social networks,
and gay community life in relation to HIV surveillance
and research [29-32]. We selected a qualitative approach
so that salient concepts and themes relevant to the study
goal could be developed [33]. That is, building from pre-
vious studies that quantified respondents theoretical use
of PrEP in their sexual lives, we selected an inductive ap-
proach so that participants could broadly explore social
and cultural influences that may play a role in their deci-
sion to use or not to use PrEP as an HIV prevention
strategy. More so, this approach allows for participants
to reflect on their intrapersonal experiences with sexual
partners, the strategies they currently incorporate to re-
duce their risk behaviors, and to consider the potential
impact that PrEP utilization may have on their fellow
community members; information which scientists, pro-
viders, and policy makers may use to consider best strat-
egies for implementation among target population
members.
Eligibility and recruitment
Thirty MSM and transgender women community mem-
bers from Alameda, Los Angeles, and San Francisco
counties (10 participants per county) were recruited to
participate in semi-structured interviews. Potential parti-
cipants learned of the study through word of mouth and
flyer postings at social service organizations, community
planning groups, and passive street recruitment. We
purposefully oversampled ethnoracial minority MSM
and transgender women to ensure that perspectives of
these groups would be adequately represented in the
dataset. Inclusion criteria were: self-identification as a
man who has sex with other men or as a transgender
woman; self-reported HIV-negative or unknown serosta-
tus; self-report of at least one male sexual partner in
the past year; and self-reported inconsistent condom use
(i.e., any report other than ‘always’ or ‘never’). We did
not enroll participants who never used condoms, as we
were interested in capturing perspectives from commu-
nity members about risk compensation and whether
men who were currently using condoms would continue
to use them with PrEP.
Data collection
Eligible participants provided verbal informed consent to
participate in an interview that covered several domains
(Table 1). A standardized statement regarding PrEP was
read verbatim to each participant by the interviewer dur-
ing data collection to ensure that all community mem-
bers had the same basic level of information regarding
the use of ARV’s as a prevention strategy (see Additional
file 1). This statement contained information on the
iPrEx Study, including all prevention services offered in
the intervention package as well as trial results. All
interviews were digitally recorded and lasted up to one
hour in length. Participants were compensated $40 for
their time. The study protocol was approved by the
UCSF Committee on Human Research.
Data analysis
Using an approach rooted in thematic analysis [34] we
incorporated several qualitative data analysis techniques,
including: inductive analysis, cross-case analysis, and
analytical coding of textual data. Our thematic analysis
process was informed by established behavioral theories
used in HIV prevention, including: the health belief
model (which notes that individual health behavior is
governed by perception of personal susceptibility to dis-
ease, severity of disease, perceived efficacy of behavior in
dealing with disease, and perceived barriers to adopting
behaviors) [35]; the social ecology theory of behavior
(which notes that health behavior is influenced by vari-
ous physical and social conditions within environments
on the person's well-being) [36]; and the theory of
planned behavior (which notes that health behaviors are
determined by an individual's health beliefs, attitudes,
personality, social norms, and willingness to comply with
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those norms) [37]. Initial inductive analyses involved dis-
covering emergent themes and patterns within the data-
set to develop a project codebook [38]. From this
preliminary codebook, code names and definitions
evolved to match emerging data during iterative analyses
of the interviews by project staff. Through reading and
coding four common transcripts, coder agreement
reached 90%, at which point the raters completed final
coding of the dataset. Memos were also written to build
theory about coding decisions and cross case analysis.
Two field research team members met regularly to build
coding consensus, to become familiar with participant
narratives, to contextualize discrepancies, and to make
coding and cross-case analysis decisions of newly uncov-
ered themes. Quotes selected for inclusion reflect the
experiences and views of participants, and were chosen
based on their relevance to the study goal. Atlas.ti soft-
ware was used to assist in data management throughout
the analysis process [39].
Results
Table 2 depicts key participant characteristics, by county.
Participants ranged between 21 to 58 years of age. Over-
all, approximately three-quarters of our sample stated
that they are employed, two-thirds reported some type
of health insurance, and all but one had completed high
school, suggesting a relatively educated sample. Al-
though many expressed personal reservations, 23 of the
30 participants (76%) indicated that they were willing to
consider the use of PrEP.
Three major themes emerged from the dataset. First,
participants displayed a considerable lack of awareness
Table 1 Study interview guide topics
Domain Examples
Demographics How would you describe your ethnicity?
Are you currently employed? What is your job or profession?
Do you currently have health insurance?
How would you describe your sexual identity?
Knowledge of PrEP and the iPrEx Study
results
Please tell me what you understand about PrEP. What have you heard, if anything?
Were you aware of the results of the PrEP trial that were announced in November 2010? What did you
think about the results when they were announced?
Are people in your community talking about PrEP? What are they saying?
Personal sexual-risk assessment How would you assess your risk for HIV infection?
Why do you think you are [low/moderate/high] risk?
How frequently do you test for HIV? What about other STDs?
Willingness to take a daily ARV Would you be willing to take a pill on a daily basis? [if yes] Can you say why? [if no] Are there any
circumstances under which you would be willing?
How would taking a pill each day work in the context of your day-to-day life and routines?
Ability to follow routine medical
monitoring
Would you be willing to test for HIV now, and then do regular HIV testing while you were taking PrEP?
What would influence your ability to make and keep regular check-up appointments with your doctor?
Acceptable side effects and potential
long-term health risks
Do you have any concerns about potential side-effects from taking PrEP? Can you give some examples?
In your opinion, do the benefits of PrEP outweigh the potential risks? Can you say why?
Associated cost and financial
considerations
Would you be willing to pay out of pocket expenses for PrEP? How much would you be willing to pay
each month?
If health insurance plans covered PrEP would you feel comfortable going to your doctor and asking for
a prescription?
How would you feel about having that information be part of your medical records and accessible to
your insurance companies?
Decision making about starting and
stopping PrEP
Under what circumstances would you might consider starting PrEP? What would be a motivator
for you?
Under what circumstances would you might consider stopping PrEP? What would make you not want
to take it anymore?
Perceived effects of PrEP in community Do you think the availability of PrEP will affect people’s willingness to use condoms?
What would be a good way to make people in your community aware of PrEP?
Overall, what is your opinion of PrEP as a method of HIV prevention [both for you and for your
community]?
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and knowledge surrounding PrEP. Second, participants
expressed ambivalence towards successfully integrating
PrEP within their existing personal HIV prevention
efforts. Finally, participants noted concerns about the
rollout of PrEP, in that they either worried that the
branding of PrEP as a prevention tool may leave out crit-
ical components of the trial intervention, or that the
scale-up of PrEP within the healthcare system may ex-
clude sub-populations of impacted communities. We
include a summary of these findings in Table 3. Below,
we contextualize each finding with reference to partici-
pant data. We acknowledge that within these themes
there exist topics where participant beliefs surrounding
PrEP acceptability were not always mutually exclusively.
Thus, we categorized findings into selected themes
based on the context in which the participant described
particular phenomena.
Finding one: Community members are unaware and/or
unknowledgeable about PrEP
By and large, participants from all counties had never
heard of PrEP. Statements such as ‘I do not know what
PrEP is. I have no knowledge of that information’ (31,
White MSM, LA) were prominent. For those who had
heard of PrEP prior to the interview, correct information
was strongly overshadowed by mis-communicated facts
and confusion with other treatments, particularly with
post-exposure prophylaxis (PEP) [40], ‘. . .There’s PrEP
and PEP, I get those two mixed up’ (42, Black MSM, SF);
‘It’s like the morning after pill so you won’t get pregnant,
I think that’s the same type of pill’ (45, Black MSM, SF).
Indeed, the notion of a ‘morning after pill’ in recounting
PrEP information was expressed by the majority of parti-
cipants who considered themselves knowledgeable about
PrEP, and suggests confusion in regards to how ARVs
function in an increasingly biomedically-focused HIV-
prevention field.
Participants who reported limited PrEP knowledge
tended to also report mistrust of medical systems and
pharmaceutical companies, as well as discrimination
within the medical industry. In particular, these issues
were salient for Black participants:
‘Because I’m suspicious of the pharmaceutical
companies, and—there are a lot of rumors about
pharmaceutical companies. Then friends of mine, who
are—especially African-American men, who are
suspicious of clinical trials. . . so there are always
issues about the Tuskegee syphilis trials, and there’s
always this suspicion, especially among a lot of Black
people I know, that these trials are just hidden ways
of genocide, and things like that—and they don’t feel
comfortable. I’m talking from the transgender thing,
the transgender girls said they’re not comfortable with
the way they [providers] look at them or treat them. . .
And that’s sad. That’s really sad, especially here in San
Francisco’ (54, Black MSM, SF).
However, these sentiments were not limited by ethno-
racial minority identity:
‘Because I just feel more capable of taking care of my
sexual health because I feel like my doctors are not
Table 2 Community member characteristics, by county
(n = 30)
Alameda
(n = 10)
Los
Angeles
(n = 10)
San
Francisco
(n = 10)
Total
sample
(n = 30)
Mean age (SD) 32 (8.74) 32 (6.16) 44.2 (10.83) 36.07 (10.30)
Employment Status
Employed 8 10 4 22 (73%)
Unemployed 2 0 6 8 (27%)
Education
<High School 1 0 0 1 (3%)
HS/GED 2 2 2 6 (20%)
Some college 6 3 6 15 (50%)
College degree 1 5 2 8 (27%)
Ethnoracial identity
Black 6 0 7 13 (43%)
Latino 2 8 0 10 (33%)
Mixed 1 0 0 1 (3%)
White 1 2 3 6 (20%)
Gender
Male 8 7 9 24 (80%)
Femalea 2 3 1 6 (20%)
Health Insurance
None 3 3 1 7 (23%)
Public 2 0 8 10 (33%)
Private 4 4 1 9 (30%)
Unspecified 1 3 0 4 (13%)
Sexual Orientation
Gay 3 7 6 16 (53%)
Bisexual 3 0 0 3 (10%)
Other sexual minority
identityb
2 0 3 5 (17%)
Heterosexuala 2 3 1 6 (20%)
PrEP willingness
Willing to use 3 4 3 10 (33%)
Willing to use, if certain
information is provided
4 5 4 13 (43%)
Not willing to use 3 1 3 7 (23%)
a Transgender participants. b This category is inclusive of all other
self-identified sexual orientation descriptors (e.g., ‘queer’).
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Table 3 Summary of community member perspectives on the uptake and implementation of PrEP at the population level
Finding Examples Considerations and/or Implications for policy
and practice
Community members are
unaware and/or
unknowledgeable about PrEP
Of those who reported no previous understanding of PrEP: Need for materials or procedures within PrEP programs
that can overcome historical mistrust of the medical system.
• Expressed mistrust of medical system • Consumer information that is simplified and clearly
written so that local community members accurately
understand PrEP findings.
• Do not believe PrEP actually exists and/or do not
believe it will work
• Enhanced efforts to disseminate findings to local
communities. This is likely to include use of venues
and media accessed by those communities.
• Did not know that any studies of an HIV prevention
pill were underway
Of those who reported previous knowledge of PrEP:
• Often confused PrEP with PEP
• Had incorrect information regarding clinical trials
• Do not see its purpose
Community members
expressed mixed interest in
receiving PrEP
Of those who expressed interest in using PrEP:
• Believe it would help connect individuals to the
healthcare system
• It is critical for information campaigns about PrEP to
focus on:
• Expressed that anything to help reduce HIV
transmission is a good thing
• (1) its efficacy at preventing HIV infection;
• Noted that PrEP already fit into their medical routine • (2) its safety;
Of those who reported conditional willingness to use PrEP: • (3) the logistical ease of the regimen and associated
medical monitoring; and
• Reported various concerns about safety and side effects • (4) programming, funding sources or opportunities that
would make PrEP affordable for low-income populations.
• Believe cost is a major barrier (both for themselves and
others)
• Need more statistics and data to make a final decision
Of those who expressed minimal to no interest in
receiving PrEP:
• Do not believe PrEP is effective enough and/or
believed condoms were a better alternative
• Feel that monitoring of side effects is burdensome
• Stated that a once-a-day regimen is not realistic
Community members noted
concerns regarding the
rollout of PrEP
Of those who noted concerns about PrEP as a package: Critical to implement PrEP as part of comprehensive
programs that combine daily pill regimens with
other strategies, such as testing and counseling
and behavioral intervention approaches.
• Believe much disinhibition and risk compensation
will occur in their communities
• Need to develop protocols that define clearly the
roles that clinical providers and community-based
providers will play in the provision of combination
prevention strategies that include PrEP and more
traditional prevention approaches (e.g., testing,
behavior change).
• Fear that ARVs would be prioritized over education,
condom use, testing and counseling
• Inclusion of diverse viewpoints in decision making
around funding priorities for HIV prevention dollars.
• Feel that messaging will not reach the communities
it needs to
Of those who noted concerns about PrEP accessibility:
• Expressed multiple fears of equity and access
• Questioned the roles and responsibilities of providers,
health insurance and pharmaceutical companies in
reducing health disparities
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capable of taking care of my sexual health. They’re
uneducated, they’re ignorant, they’re very
heterocentric, almost homophobic. It just doesn’t
jive. . . I mean it was the US government that was
infecting people with syphilis, gonorrhea, and other
STIs to see what they’re gonna do. So I will never
trust the state to invest itself in my health and my
awareness, as a poor person’ (25, White MSM,
Alameda).
A minority of participants noted that they believed
PrEP would be ineffective, ‘this pill is a good idea but I
don’t think it’s gonna work. . .’ (44, Black MSM, SF).
Others expressed that they did not see the purpose of
PrEP, ‘Why take the medication if you don’t need to? If
you’re having so-called safe sex with a condom? With
the use of a condom, then there’s no need to ingest any
medication’ (36, Latino MSM, LA). Nonetheless, upon
hearing of the efficacy of the iPrEx Study results several
participants felt that PrEP would make a ‘good back-up
plan,’ (e.g., in cases where a condom broke), but that
more information was needed.
Finding two: Community members expressed mixed
interest in personally receiving PrEP
Given the format of the semi-structured interview, and
recognizing that the interview was the first time that
many participants learned of PrEP (or gained correct
PrEP information), thoughts and perspectives regarding
their personal willingness to use PrEP often shifted dur-
ing the interview process, and related to six key factors:
the individual’s sexual-risk assessment; beliefs that PrEP
would connect them to care and treatment; knowledge
of side effects; perceived effectiveness of the interven-
tion; self-awareness of medication adherence; and cost.
With respect to personal risk assessment, several com-
munity members reflected on their preferences to not
use condoms, as well as instances where they have previ-
ously engaged in risky sexual behaviors. These indivi-
duals believed that an intervention such as PrEP might
fit well with their current behaviors:
‘Well to be honest, I don’t like using condoms myself.
If I took PrEP, then I still wouldn’t use a condom, but
I would feel better taking—I would be less worried or
paranoid about getting HIV by using PrEP than I
would if I weren’t using PrEP,’ (48, Black MSM, SF).
‘The reason I would take it is because I know that
sometimes my behavior does get risky, especially
when I use drugs. . . so yeah, I absolutely would take
anything to prevent anything if my judgment goes
down the toilet and I don’t use protection,’ (29, Black
MSM, Alameda).
One major motivator for the uptake of PrEP, as
described by our participants, is its potential to link indi-
viduals to care. For example, participants described how
community members who have traditionally not
accessed health services could be linked to prevention
programs if a PrEP intervention were in place:
‘And when it’s prescribed by a doctor, it’s part of your
entire medical treatment. . . and so I think that’s
important, and that’s good—yeah, we’re gonna
prescribe this to you but we’re gonna also require you
to have counseling and explain to you this and talk
about abstinence and condom and low-risk and
needle exchange and the nine thousand things that
you should be thinking about, and not just pop a pill,
have fun,’ (54, Black MSM, SF).
In addition to having the potential to link individuals
to prevention services, participants noted the potential
of PrEP to link community members to treatment ser-
vices if they were to seroconvert while on PrEP, ‘But the
good part will be, if they will get infected, they will be
linked to care more easily,’ (25, Latina transwoman, LA).
Importantly, participants’ concerns and knowledge of
PrEP side effects played a major role in swaying their
personal pendulum of willingness to take PrEP: ‘My de-
cision would be all because of side effects,’ (32, Mixed-
race MSM, Alameda). Given the mild side effects in the
iPrEx study, there was a spectrum of opinions regarding
what tolerable side effects may be. In general, if the side
effects were not severe (e.g., headache, nausea, loss of
sleep) or faded over time then participants were more
likely to report willingness to use PrEP. Some side
effects that participants reported as ‘deal-breakers’ were
long-term damage to kidneys, sexual dysfunction (e.g.,
failure to maintain an erection), and ‘serious bone dam-
age.’ A few noted fears of complications with existing
morbidities:
‘Then that’s another thing that would scare me. ‘Cause
I’m also—I’m a diabetic. I have Type 2 diabetes, and I
also have high blood pressure. . . Usually a lot of
people who suffer from diabetes are already having
kidney problems. . . If I take this medicine will it make
it worse?’ (49, Black transwoman, SF).
Still, there were a select number of participants who
explained that ‘there’s gonna be side effects to every-
thing, no matter what you do,’ (39, White MSM, SF), so
they would be willing to take PrEP, as an intervention
package, regardless of the side effects.
Participants also weighed the efficacy of PrEP in their
willingness decisions. Those who focused on adherence
and a 70% PrEP efficacy tended to speak more favorably
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of ARVs as prevention than those who focused on the
overall 44% efficacy:
‘Well, I think—I’m in a high risk, because I don’t like
using condoms when I have sex also. So if its’ been
proven to actually reduce to 70% of the people who
took the PrEP drug, then I’d be willing to try it also. I
mean, as long as there are no side effects or anything
like that, you know?’ (48, Black MSM, SF).
‘Well I’m just saying, if you take something every day,
and you only have a 44% chance of preventing, getting
what it’s suppose to prevent, then we’re not even
talking 50/50, we’re talking a little less than 50%, or a
little more than 50% getting HIV. So it’s kind of grim,’
(59, White MSM, SF).
When poised with the question of whether taking a
daily pill would interrupt their regular health service
schedule, those who had established routines exclaimed:
‘No. I already see a doctor once a month. I see my
psychiatrist once a month, and I see my primary care
doctor once every six months, so I don’t have a
problem, actually, adhering to a certain regimen,’ (48,
Black MSM, SF).
In fact, those who reported daily use of other medica-
tions such as high-blood pressure, psychiatric, or dia-
betes medications, as well as multi-vitamins and other
supplements, tended to speak favorably on their personal
willingness to use PrEP.
Others commented on the added responsibility of tak-
ing a daily pill, ‘it’s a little hard for me to do something
on a regular basis, all the time, every time, at the same
time,’ (46, Latino MSM, Alameda); which would be com-
pounded by the ‘burden’ of ongoing regular medical
monitoring. In light of this consideration, some partici-
pants alluded to the thought of occasional (i.e., intermit-
tent) PrEP use, as well as other dosing alternatives that
could make adherence more acceptable:
‘If it was something I could take monthly, PrEP would
be amazing. Like first of the month when I get paid, I
take a pill, awesome! I can calendar it out. But on a
daily basis man, that would be difficult!’ (25, White
MSM, Alameda).
Our participants described that the next major barrier
to PrEP uptake, both in terms of personal and commu-
nity level perceptions, was that of cost. In discussing
their financial threshold for PrEP, reported values ranged
between $5 and $500 per month; with the majority of
participants describing an average of $20 to $25 per
month as a ‘reasonable’ amount. Some descriptive
thresholds included, ‘the price of a cup of coffee,’ or
‘about the same as daily vitamins,’ and for those with in-
surance, ‘about an average drug co-pay.’ These amounts
and associated willingness to use PrEP, however, were
based on theoretical situations if cost was at least par-
tially covered. The realities of PrEP payment and willing-
ness to use varied by individual; ‘. . .because I’m poor, so
I imagine it would affect the chance of me using it. And
my friends are poor,’ (35, Latino MSM, LA). In one ex-
treme case, a non-insured participant commented that
without any type of insurance or financial assistance, the
prospect of acquiring disease and receiving no-cost ser-
vices would be most opportune for his situation:
‘I would be very honest, but if you are asking me to
pay $12,000 for a preventive pill, whereas if I get the
virus, I go to a free clinic and I’m going to get all the
drugs for free, as stupid as it sounds, I’d probably
prefer to have the virus and have my drugs for free. . .’
(37, Latino MSM, LA).
Even still, for some, the use of male condoms made
for a less burdensome and more cost-effective choice.
‘Using a condom is much better. . . because just no tests.
I don’t have to go to the doctor every month, I don’t
have to be tested. I don’t’ have to keep paying to get the
medicine—It’s a hassle,’ (22, Black MSM, Alameda).
Finding three: Community members noted concerns
regarding the rollout of PrEP
The ways in which PrEP will be presented to the com-
munity, and its potential to impact sexual-risk behavior,
was of utmost importance to participants. Most in the
study believed that their personal sexual-risk behaviors
would not increase if they were to begin a PrEP regimen,
‘and I don’t think it would encourage me to engage in
more high-risk behavior,’ (54, Black MSM, SF). However,
participants expressed fears of disinhibition occurring
among their peers at the population level:
‘Well, in the community, the African American
community and gay community, there’s not a whole
lot of condom use going on anyway. So if they hear
about this drug—it’s like, oh it prevents you from
getting HIV! People are gonna run with that. It’s
gonna be like-people will be tryin’ to get these pills
like they get street drugs. . .. so it will lessen the
condom use, definitely. . .’ (30, Black MSM, Alameda).
‘Oh my god! I think it would be a crazy thing. It
would be like—people would be popping all these pills
and not taking care of themselves. . . Like not using
Galindo et al. Implementation Science 2012, 7:116 Page 8 of 13
http://www.implementationscience.com/content/7/1/116
condoms, because they feel that, ‘oh I’m not
going to get it, because I’m taking these pill,’ or ‘oh,
I could have unprotected sex and go pop a
pill’. . . I just feel that would happen in my
community. Just crazy, just—oh ya,’ (25, Latina
transwoman, LA).
It should also be noted that a select number of
college-educated participants reported that population-
level disinhibition may be unfounded speculation. These
individuals attributed their sentiments to their percep-
tion that condomless sex was already occurring within
MSM populations:
‘It’s been my experience that people’s willingness to
use condoms has already decreased significantly,
and so I don’t think that this is going to add
to that decrease that much. It seems like this is a
good response to behaviors that are already
happening – the decrease of condom
usage,’ (28, White MSM, SF).
Many participants noted that the delivery of PrEP, as
suggested in previously provided quotes, should be more
than promotion of daily ARV adherence. Participants
stated fears that the medication portion of a PrEP inter-
vention would be prioritized over condom use and edu-
cation. Some participants explained that sometimes ‘life
shows up’ and that for those who are not connected to
stable social support and clinical care services, ‘it’s not
gonna be a real successful thing to get them into coun-
seling,’ (47, Black transwoman, Alameda), because they
are already lacking adequate access.
In highlighting the significance of the educational
component of a PrEP intervention package, a younger
San Franciscan, who happened to be a health educator,
framed the discussion in a historical context:
‘We did a great deal of education when the
HIV crisis hit and we learned that condoms
prevent HIV, and I don’t think that we continue
to do that kind of education that happened.
And so I think it just needs a massive education
campaign and a community buy-in. I think
that’s a large part of it, too, and the community
doesn’t have that buy-in right now. . .’
(28, White MSM, SF).
Participants often discussed the notion of equity and
access in relation to health disparities, as well as the
question of who should financially support an effective
PrEP rollout. One participant exclaimed that the respon-
sibility of marketing PrEP to populations affected by the
epidemic should fall on pharmaceutical companies who
manufacture ARVs, ‘I would personally say that whoever
created this medication, if they’re going to charge
$12,000. . . then they should also have money set aside
to also target the communities,’ (36, Latino MSM, LA).
Feelings of, ‘I think this would actually cause people to
feel discriminated against, because it’s the people who
can afford and the people who can’t,’ (42, White MSM,
LA), were also common among the narratives. While
many framed the issue of access along socioeconomic
lines, the only participant to possess a doctoral degree
framed the issue of equity in regards to the belief that
resources will be put towards HIV uninfected persons
and not to those living with HIV. ‘It seems as like
[though] more of the research has been going to pre-
venting it [HIV], and not so much the people who actu-
ally have it,’ (42, White MSM, LA). Another participant
concisely expressed the response of others in the study,
‘So obviously, if this is going to exist for the community,
then hopefully something will be done in which every-
one can afford it—not just the wealthy or the upper
middle class,’ (36, Latino MSM, LA).
Individuals stated that ‘high-risk folks,’ including those
with multiple partners, those who dislike the use of con-
doms, those who practice serosorting (i.e., choosing sex-
ual partners based on their perceived HIV status), those
who use illicit substances, and those who engage in sex
work, would be good candidates for tailored PrEP mar-
keting and implementation:
‘I think—in looking at the big issue for me is, how do
we—the prevention part. How do we help the
prevention part of it? When people are still gonna
make stupid decisions, which is, let’s call it what it is.
And that’s the high-risk folks. Then this is gonna be
something good for them. . . so I think something like
this could benefit a low socioeconomic community
like ours, low education—and low-educated not just
college, but just on the issue of protection,’
(31, Latino male, LA).
‘But the people that really need it are the people that
are living in SROs [single room occupancy;
government-subsidized housing], on GA [general
assistance], Social Security SSI [supplemental social
security income] or whatever they’re on. . . But
if they gotta pay for it, you’re just gonna
be sitting there with a bunch of pills,’
(44, Black MSM, SF).
By underscoring the significance of PrEP utilization
and its importance in reducing sexual and gender mi-
nority health disparities, the following reflections of an
older Black transwoman, who reported often engaging in
unprotected receptive anal intercourse, puts into context
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the potential of translating iPrEx Study results into
population-level settings:
‘Well, I didn’t know, like I told you when I came in,
much about it [PrEP]. I’ve heard about it. But I think I
have a more clear understanding, and I think it would
be something very good for the LGBT community.
We as a people are very sexually active. That’s our
stigma. We probably always will be. We have younger
LGBT members coming up, we have trans, lesbians,
gays or whatever, and I think this drug would be just
what is needed to help our community, to save our
community, and I’m very much interested in learning
more about it. I really am. . . We do get individuals
that need some prevention in life and want some type
of prevention, and this particular drug seems like it
will do, if only for the 44 percent. It will do what
needs to be done. The rest is up to me and to each
individual that takes it, to make sure that we’re
following through with the counseling, following
through with the doctor visits, just to make sure, or
following through with changing our diet, our eating
habits. And in cases of, it has to be a condom, making
sure that we use a condom, until we can be
conclusive that this drug can be taken without the use
of a condom and still prove to be successful at
lowering the cases of HIV and AIDS in our
community,’ (47, Black transwoman, Alameda).
Discussion
Previous work surrounding the translation of iPrEx
Study results into community settings noted that the ef-
fectiveness of using PrEP as an HIV prevention strategy
could be offset by: low or intermittent use of ARVs, dis-
inhibition and risk compensation, and/or minimal up-
take and limited access to available medications [41-43].
Our results, which revealed a deficiency in knowledge
surrounding PrEP and other biomedical interventions is
consistent with these previous studies. Our data further
build upon the innovative qualitative work of prior inter-
national studies with the population [29-32], and add to
the context of misunderstandings of PrEP information in
communities by noting a lack of accurate information
dissemination within these populations, as well as much
confusion with PEP treatments. Additionally, our find-
ings complement previous work by reporting that bar-
riers such as cost, access, safety, equity, and education
influence individual perceptions about the efficacy of
PrEP implementation at the population level. However,
our results also show that motivators for PrEP adoption,
such as increased protection against HIV and connection
to the healthcare system, could ease uncertainties asso-
ciated with PrEP uptake. As our data collection tool
included a synopsis of the iPrEx Study, the majority of
our sample underscored the fact that PrEP should be
delivered in the way that it was tested in the clinical
trial: as an integrated prevention package that is not
simply taking a daily ARV, but inclusive of education,
counseling, STI screenings, condom promotion, and
side-effect monitoring. Also consistent with previous
PrEP work, fears were expressed that the condom pro-
motion component of the intervention package would
fall out over time and that disinhibition would occur
[44]; however, many of our participants believed coun-
seling and educational components of a comprehensive
package of services would help compensate for these
tendencies.
Additional studies are underway to answer questions
brought on by the iPrEx results, and to address concerns
raised by our study participants. The HIV Prevention
Trials Network is conducting an international intermit-
tent PrEP use feasibility study [45]. In San Francisco, CA
and Miami, FL demonstration projects examining PrEP
administration in sexual health city clinics will begin in
2012 [46]. A 72-week open label extension of the iPrEx
Study is currently enrolling participants to assess the on-
going efficacy, safety and adherence of PrEP [47]. Under-
standing the perspectives of community members, like
those of the present study, is imperative as these indivi-
duals will actually be the persons accessing and utilizing
PrEP in the near future.
Recommendations
First, the way in which public health professionals frame
PrEP will be a key factor in its acceptability by commu-
nities most impacted by the epidemic. Eradication of in-
fectious diseases cannot occur through microbial
medications alone; and the reduction of HIV incidence
and associated health disparities will most likely involve
a combination of biomedical and sociobehavioral inter-
ventions [48,49]. A critical component of this combin-
ation prevention approach will be the delivery of
accurate information to communities that translates
findings in a way that is factual and does not lead popu-
lations to jump to the wrong conclusions. However, thus
far, delivery of truly accurate PrEP information has yet
to reach those groups disproportionately affected by the
HIV epidemic. For example, our dataset notes that mar-
keting PrEP as ‘A pill a day to keep HIV away’ [50] is not
a completely accurate description of PrEP, and under-
mines community members’ ability to comprehend and
accept the complexity involved with a complete PrEP
intervention. One way in which professionals can en-
hance their ability to increase PrEP knowledge and com-
munity member buy-in would be the use of community
mobilization strategies. Community mobilization creates
social change by building awareness of critical health
issues and empowers community members to take
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charge of their healthcare needs through a collective, en-
gaging and iterative process [51]; and has been effective
in other population-level HIV prevention efforts [52].
Second, the way in which providers package PrEP as an
intervention will be a key factor in its success as a preven-
tion strategy for those most vulnerable to HIV infection.
Previous work underscores the belief that the delivery of
PrEP at the population level should be a multi-level inter-
vention that cuts across individual and structural eco-
logical levels in order to have optimal impact [41,42,48].
While there is currently no minimum standard of care for
the provision of PrEP in community settings, there is con-
sensus that medical monitoring, STI and HIV testing, be-
havioral risk reduction counseling, access to medications,
condom promotion and distribution, public health cam-
paigns, and coordination with local stakeholders are all
crucial components that will either hinder PrEP imple-
mentation or add to its success. The questions of who,
what, where, and how PrEP will be delivered now arise. As
noted by our study population, mistrust with medical set-
tings still exists within communities impacted by HIV, and
even those with access to providers expressed concern of
homophobia and non-culturally competent staff in the
medical field. The promise of PrEP to incorporate bio-
medical and sociobehavioral approaches make the use of
implementation science an ideal conceptual framework
from which to consider delivery at the population level,
and to answer the pragmatic and logistical questions
involved with its administration [53].
Finally, the way in which costs associated with PrEP
are absorbed or subsidized by private insurance compan-
ies, federal and local government programs, and/or
pharmaceutical companies will be a key factor in its abil-
ity to reduce HIV-related health disparities by curbing
the epidemic among those most-impacted. In the US,
off-label costs of TruvadaW are approximately $11,000
per year, which far exceeds the threshold of acceptable
financial burden reported by our study sample. An
examination of remunerative potential, conducted prior to
the iPrEx Study results, noted that given a 50% efficacy
rate, PrEP at the population level would not be sufficient
to meet the standard of US cost-effectiveness [54]. More-
over, the study suggests that in order for PrEP to be at-
tractive it would need to be targeted within populations at
greater risk for HIV infection, including young and high-
risk MSM. The manufacturers of TruvadaW, have recently
received approval from the Federal Drug Administration
for the use of TruvadaW as prevention [55]. While this has
hopeful implications for those community members with
access to healthcare, as noted by participants, this could
create a situation of the ‘haves and have-nots,’ with an un-
equal distribution of medication and services. In an ever-
increasing, resource-limited HIV prevention field, officials
must decide if combination prevention approaches are the
best use of funds when other, more cost-effective, strat-
egies already exist [56-58]. This is a particularly important
consideration as providers attempt to balance biomedical-
focused interventions, like treatment as prevention and
testing and linkage to care, with prevention programs that
focus on the social dimensions of HIV prevention efforts
[59,60].
Limitations
While data from this qualitative investigation present
new and insightful understandings that help frame the
discussion of PrEP implementation at the population
level, it possesses several limitations. First, we were only
able to gather the perspectives of individuals in three
California regions. Given this, we are unable to
generalize to other geographic locations as the experi-
ences of those from rural areas, or other metropolitan
areas, may vary considerably from individuals in our
sample. However, participants represent three counties
in California most impacted by the HIV epidemic. Sec-
ond, being able to contrast community member perspec-
tives with those of medical providers would have added
another level of insight into the implementation of PrEP;
indeed, in light of this, medical provider insight has been
reported elsewhere [61]. Finally, the interview format
may have introduced bias by providing participants with
information on PrEP. Despite these limitations, the
current study provides innovative insight into commu-
nity member perspectives of PrEP and informs future
directions and implications for its implementation.
Conclusions
The advancement of PrEP for use as a new weapon in
the arsenal to combat HIV transmission is promising. As
the policy discussion regarding PrEP implementation
continues to evolve, key stakeholders should make cer-
tain that: the communities most impacted by the HIV
epidemic are knowledgeable about PrEP; that questions
and concerns regarding medical mistrust and side effects
are addressed; that PrEP is accessible financially; and
that PrEP is a complete intervention package inclusive
of education, condom promotion and linkage to care.
Even with clinically proven individual-level efficacy, if
not packaged, implemented, and sustained properly,
PrEP could increase HIV health disparities at the popu-
lation level that it initially had the potential to eliminate.
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